- 1 Supplementary Material for
- 2

3 SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B 4 cell response in primary antibody deficiency patients

5

Frank J. Lin^{1,9}, Alexa Michelle Altman Doss^{2,9}, Hannah G. Davis-Adams¹, Lucas J. Adams³,
Christopher H. Hanson¹, Laura A. VanBlargan¹, Chieh-Yu Liang^{1,3}, Rita. E. Chen^{1,3}, Jennifer Marie
Monroy¹, H. James Wedner¹, Anthony Kulczycki¹, Tarisa L. Mantia¹, Caitlin C. O'Shaughnessy¹,
Saravanan Raju³, Fang R. Zhao¹, Elise Rizzi¹, Christopher J. Rigell¹, Tiffany Biason Dy¹, Andrew
L. Kau^{1,4}, Zhen Ren¹, Jackson Turner³, Jane A. O'Halloran¹, Rachel M. Presti^{1, 6}, Daved H.
Fremont³, Peggy L. Kendall¹, Ali H. Ellebedy^{3, 5, 6}, Philip A. Mudd^{6, 8}, Michael S. Diamond^{1,3,5,6, 7},
Ofer Zimmerman^{*1}, and Brian J. Laidlaw^{*1}

- 13
- 14
 15 * Correspondence should be addressed to Brian Laidlaw (brian.laidlaw@wustl.edu) and Ofer
 16 Zimmerman (zimmero@wustl.edu)
- 17

18 **This PDF includes:**

- 19 Supplementary methods
- 20 Supplementary references
- Fig. S1. Baseline phenotype of PAD patients and healthy donor cohorts.
- 22 Fig S2. COVID-19-experienced PAD patients display elevated RBD-specific B cell response
- 23 following primary vaccination series.
- Fig. S3. COVID-19-naive PAD patients display elevated RBD-specific B cell response following
- 25 booster vaccination.
- 26 Fig. S4. Isotype composition of SARS-CoV-2 RBD-specific memory B cell response following
- 27 vaccination in PAD patients.
- Fig. S5. RBD-specific memory B cells from PAD patients display reduced CD11c expression class.
- 30 Table S1. Characteristics of patient cohort
- 31 Table S2. Cellular phenotype of patient cohort
- 32 Table S3. PAD patient laboratory values
- 33 Table S4. PAD patient responses to other vaccine antigens at time of diagnosis

34 SUPPLEMENTARY METHODS

35 Preparation of peripheral blood mononuclear cells. Patient blood was collected in sodium 36 citrate cell preparation tubes (BD Biosciences). Tubes were centrifuged at room temperature for 37 30 minutes at 1650 x g without brake. The mononuclear cells and plasma layer were then 38 transferred to a 50mL conical and centrifuged at room temperature for 10 minutes at 256 x g. 39 Supernatant was removed without disturbing the cell pellet. Cells were resuspended in PBS and 40 all cells of the same subject were combined into one 15-mL conical tube. Cells were centrifuged 41 as above. Supernatant was removed without disturbing the cell pellet and cells were 42 resuspended in 5mL of ACK lysing buffer (Thermo Fisher) for 5 minutes. Cells were washed 43 with PBS, counted, washed again with PBS, resuspended in 10% dimethylsulfoxide in FBS at 10⁶ cells per mL and aliquoted into cryovials. Cryovials were transferred to a freezing container 44 45 (Daigger Scientific, Mr. Frosty) and placed in a -80°C freezer overnight before being transferred 46 to liquid nitrogen for storage. 47 48 Antibodies for flow cytometry staining. Staining for flow cytometry was performed using 49 cryopreserved PBMC samples. Cyropreserved samples were thawed in a 37 °C water bath and 50 added to tube containing RPMI with 10% FBS and 1% Penicillin Streptomycin solution (Fisher). 51 Cells were then centrifuged at 300x g at room temperature, resuspended in 10% RPMI, and 52 counted. Cells were then aliquoted to a 96 well plate and centrifuged at 810 x g for 2 minutes at 53 4 °C. The cells were then washed with PBS containing 2% FBS, centrifuged, and then incubated 54 with the primary antibody mix for 30 minutes on ice. Samples that were stained with tetramer 55 containing antibody cocktail were incubated for 45 minutes. Cells were then washed three times 56 with 2% PBS and incubated with secondary antibody mix for an additional 30 minutes. Samples

were then washed an additional three times with 2% PBS before being resuspended for flow
cytometry analysis. Flow cytometry data were acquired on a Cytek Aurora and were analyzed
with FlowJo software (TreeStar).

60

The following antibodies were used for flow cytometry staining: Brilliant Violet 711(BV711) anti-CD11c (301630), BV750 anti-CD19 (302262), allophycocyanin (APC)/Fire 810 anti-CD3 (344858), BV510 anti-IgD (348220), BV605 anti-IgM (314524), phycoerythrin (PE)/Dazzle 594 anti-CXCR5 (356928), APC anti-his (362605), PE/Fire 810 anti-CD27 (302859), APC/Fire 750 anti-CD20 (302358), Zombie NIR (423106), phycoerythrin-indotricarbocyanine (PE-Cy7) anti-CD71 (334112), BV650 BV570 anti-CD45RO (304226), FITC anti-CCR7 (353216), BV605 antiHLA-DR (307640), Alexa Fluor 700 anti-CD4 (344622), Alexa Fluor 594 anti-CD8 (301056),
peridinin chlorophyll protein Cy5.5 (PerCpCy5.5) (304122), PE/Fire 810 anti-CD27 (302859),
BV421 anti-ICOS (313524) (all from Biolegend); Biotin anti-IgG3 (OB9210-08), Alexa Fluor 555
anti-IgG2 (OB907032), PE anti-IgG1 (OB905409), FITC anti-IgA (CBL114FMI), Brilliant Blue 700
(BB700) anti-CD38 (BDB566445), PE-Cy7 anti-PD1 (BDB561272) (all from Fisher).

72 His-tagged SARS-CoV-2 protein purification. Genes encoding SARS-CoV-2 Wuhan-Hu-1 73 spike protein (residues 1-1213, GenBank: MN908947.3), the Wuhan-Hu-1 RBD (residues 319-74 514), and B.1.1.529 (BA.1) spike protein were cloned into a pCAGGS mammalian expression 75 vector with a C-terminal hexahistidine tag. Both spike proteins were prefusion stabilized and 76 expression optimized with six proline substitutions (F817P, A892P, A899P, A942P, K986P, 77 V987P), with a disrupted S1/S2 furin cleavage site and a C-terminal foldon trimerization motif 78 (YIPEAPRDGQAYVRKDGEWVLLSTFL) (50). Expi293F cells were transiently transfected, and 79 proteins were recovered via cobalt-charged resin chromatography (G-Biosciences) as

80 previously described (34, 35).

81 HLA class II tetramers. HLA class II tetramers representing the HLA-DPA1*01:03/HLA-

82 DPB1*04:01-restricted SARS-CoV-2 spike (S) protein epitopes S₁₆₇₋₁₈₀ (TFEYVSQPFLMDLE)

83 and S₈₁₆₋₈₃₀ (SFIEDLLFNKVTLAD) were constructed by cloning the relevant peptides into an

84 AbVec vector system containing the appropriate HLA alpha and beta chains linked to the

peptide of interest via a flexible linker at the N-terminus of the beta chain (41–43). This system

86 includes corresponding leucine zipper motifs on the alpha and beta chains to promote HLA

87 monomer stability. Proteins were expressed in 293F cells transfected with the appropriate

88 AbVec vector. Purified HLA monomer was biotinylated with BioA enzyme in biotinylation buffer

89 (0.2 M NaCl, 0.1 M Tris pH7.5, 5 mM MgCl₂, 5 mM ATP, 0.4 mM Biotin, 5 uM Leupeptin, 1 uM

90 Pepstatin, and 0.2 mM PMSF). The monomer was then tetramerized and fluorochrome labeled

91 by adding Streptavidin-R-Phycoerythrin (Agilent) to the S₁₆₇₋₁₈₀ monomer or Streptavidin-

92 Allophycocyanin (Agilent) to the $S_{816-830}$ monomer (51).

Focus reduction neutralization test. Neutralizing antibody titers were performed with
 authentic SARS-CoV-2 strains and variants as previous described (24).

95

96 SUPPLEMENTAL REFERENCES

97 51. C.-L. Hsieh, J. A. Goldsmith, J. M. Schaub, A. M. DiVenere, H.-C. Kuo, K. Javanmardi, K. C.

98 Le, D. Wrapp, A. G. Lee, Y. Liu, C.-W. Chou, P. O. Byrne, C. K. Hjorth, N. V. Johnson, J. Ludes-

99 Meyers, A. W. Nguyen, J. Park, N. Wang, D. Amengor, J. J. Lavinder, G. C. Ippolito, J. A.

100 Maynard, I. J. Finkelstein, J. S. McLellan, Structure-based design of prefusion-stabilized SARS-

101 CoV-2 spikes. *Science*. 369, eabd0826 (2020).

102 52. R. A. Willis, V. Ramachandiran, J. C. Shires, G. Bai, K. Jeter, D. L. Bell, L. Han, T. Kazarian,

103 K. C. Ugwu, O. Laur, S. Contreras-Alcantara, D. L. Long, J. D. Altman, Production of Class II

- 104 MHC Proteins in Lentiviral Vector-Transduced HEK-293T Cells for Tetramer Staining Reagents.
- 105 *Curr Protoc.* 1, e36 (2021).





106 Figure S1. Baseline phenotype of PAD patients and healthy donor cohorts. (a) 107 Representative B cell flow cytometry gating scheme. (b) Percentage of live cells that are B 108 (CD19⁺CD3⁻) cells at T1 in patient cohorts (left). Percentage of B cells that are activated (lgD^{lo}) 109 cells in patient cohorts (middle) Percentage of B cells that are memory (IgD^{lo}CD27⁺) cells in 110 patient cohorts. (right). (c) Percentage of live cells that are T (CD3⁺CD19⁻) cells at T1 in patient 111 cohorts. (left) Percentage of T cells that are CD4⁺ (CD4⁺CD8⁻) cells in patient cohorts (middle left). 112 Percentage of T cells that are CD8⁺ (CD8⁺CD4⁻) in patient cohorts (middle right). Ratio of CD4⁺ 113 to CD8⁺ T cells (right). (d) Serum neutralizing activity against WA1/2020 (left) and B.1.617.2 (right) 114 at T1. Non-responder defined as PAD patients in which the CD19⁺ IgD¹⁰ Spike⁺ B cells response 115 was <0.02% of total B cells at T1. Statistical analyses were performed using a one-way ANOVA 116 with Fisher's least significant difference testing in b, c; or using an unpaired t-test in d. Error bars 117 were calculated based on the standard error of the mean. (*, p < 0.05; **, p < 0.01).

118



Figure S2

119 Figure S2. COVID-19-experienced PAD patients display elevated RBD-specific B cell 120 response following primary vaccination series. (a) Percentage of activated RBD⁺ cells 121 amongst the B (Live CD19⁺ CD3⁻) cell population in the healthy donor (left, white), COVID-19-122 naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts. 123 Aggregate of mean percentage of B cells that are RBD⁺ activated cells in all groups is shown on 124 right. (b) Percentage of memory (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁺) RBD⁺ cells amongst the B cell 125 population in the healthy donor (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-126 experienced PAD (middle, green) cohorts. Aggregate of mean percentage of B cells that are RBD⁺ 127 memory cells in all groups is shown on right. (c) Percentage of double negative (IgD^{lo} CD20⁺ 128 CD38^{int-lo} CD27⁻) RBD⁺ cells amongst the B cell population in the healthy donor (left, white), 129 COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle, green) cohorts. 130 Aggregate of mean percentage of B cells that are double negative RBD⁺ cells in all groups is 131 shown on right. (d) Percentage of non-class-switched (IgD⁺ CD20⁺ CD38^{int-lo} CD27⁺) RBD⁺ cells 132 amongst the B cell population in the healthy donor (left, white), COVID-19-naïve PAD (middle, 133 red), and COVID-19-experienced PAD (middle, green) cohorts. Aggregate of mean percentage 134 of B cells that are RBD⁺ non-class-switched cells in all groups is shown on right. Statistical 135 analyses were performed using a mixed effects model (for trends found between time points) or 136 two-way ANOVA (for trends found between groups in the aggregate graphs) with Fisher's least 137 significant difference testing. Significance testing between time points was limited to comparisons 138 relative to T1. On the aggregate graphs, all error bars were calculated based on the standard 139 error of the mean. Above the aggregate graphs, an orange asterisk indicates a comparison 140 between the COVID-19-naïve and COVID-19-experienced groups, and a purple asterisk indicates 141 a comparison between the COVID-19-experienced and healthy donor groups (*, p < 0.05; **, p142 0.01; ***, p<0.001; ****, p<0.001).

143



Figure S3

144 Figure S3, COVID-19-naive PAD patients display elevated RBD-specific B cell response 145 following booster vaccination. (a) Percentage of activated RBD⁺ cells amongst the B (Live 146 CD19⁺ CD3⁻) cell population in the healthy donor (left, white), COVID-19-naïve PAD (middle left, 147 red), and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of mean 148 percentage of B cells that are RBD⁺ activated cells in all groups is shown on right. (b) 149 Percentage of memory (IgD^{lo} CD20⁺ CD38^{int-lo} CD27⁺) RBD⁺ cells amongst the B cell population 150 in the healthy donor (left, white), COVID-19-naïve PAD (middle, red), and COVID-19-151 experienced PAD (middle, green) cohorts. Aggregate of mean percentage of B cells that are 152 RBD⁺ memory cells in all groups is shown on right. (c) Percentage of double negative (IgD^{lo} 153 CD20⁺ CD38^{int-lo} CD27⁻) RBD⁺ cells amongst the B cell population in the healthy donor (left, 154 white), COVID-19-naïve PAD (middle, red), and COVID-19-experienced PAD (middle, green) 155 cohorts. Aggregate of mean percentage of B cells that are double negative Spike⁺ cells in all 156 groups is shown on right. (d) Percentage of non-class-switched (IgD⁺ CD20⁺ CD38^{int-lo} CD27⁺) 157 RBD⁺ cells amongst the B cell population in the healthy donor (left, white), COVID-19-naïve 158 PAD (middle, red), and COVID-19-experienced PAD (middle, green) cohorts. Aggregate of 159 mean percentage of B cells that are RBD⁺ non-class-switched cells in all groups is shown on 160 right, pre-boost group consists of the last sample obtained from each patient prior to booster 161 vaccination. Statistical analyses were performed using a mixed effects model (for trends found 162 between time points) with Fisher's least significant difference testing. Significance testing 163 between time points was limited to comparisons relative to pre-boost (*, p < 0.05). On the aggregate graphs, error bars were calculated based on the standard error of the mean. 164 165



Figure S4

166 Figure S4. Isotype composition of SARS-CoV-2 RBD-specific memory B cell response 167 following vaccination in PAD patients. (a) Percentage of RBD⁺ memory B cells that are IgG1⁺ 168 in the healthy donor (left, white), COVID-19-naïve PAD (middle left, red), and COVID-19-169 experienced PAD (middle right, green) cohorts. Aggregate of mean percentage of IgG1⁺ cells in 170 all groups is shown on right. (b) Percentage of RBD⁺ memory B cells that are IgM^+ in the healthy 171 donor (left, white), COVID-19-naïve PAD (middle left, red), and COVID-19-experienced PAD 172 (middle right, green) cohorts. Aggregate of mean percentage of IgM⁺ cells in all groups is shown 173 on right. (c) Percentage of RBD⁺ memory B cells that are IgA^+ in the healthy donor (left, white), 174 COVID-19-naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right, green) 175 cohorts. Aggregate of mean percentage of IgA^+ cells in all groups is shown on right. (d) 176 Percentage of RBD⁺ memory B cells that are IgG2⁺ in the healthy donor (left, white), COVID-19-177 naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts. 178 Aggregate of mean percentage of $IgG2^+$ cells in all groups is shown on right. (e) Percentage of 179 RBD⁺ memory B cells that are IgG3⁺ in the healthy donor (left, white), COVID-19-naïve PAD 180 (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of 181 mean percentage of IgG3⁺ cells in all groups is shown on right. Statistical analyses were 182 performed using a two-way ANOVA (for trends found between groups in the aggregate graphs) 183 with Fisher's least significant difference testing. On the aggregate graphs, error bars were 184 calculated based on the standard error of the mean. Above the aggregate graphs, an orange 185 asterisk indicates a comparison between the COVID-19-naïve and COVID-19-experienced 186 groups (*, p < 0.05). 187





188 Figure S5. RBD-specific memory B cells from PAD patients display reduced CD11c 189 **expression class**. (a) Percentage of RBD⁺ memory B cells that are CD11c⁺ in the healthy 190 donor (left, white), COVID-19-naïve PAD (middle left, red), and COVID-19-experienced PAD 191 (middle right, green) cohorts. Aggregate of mean percentage of CD11c⁺ cells in all groups is 192 shown on right. (b) Correlation between percentage of RBD⁺ memory B cells that are IgG1⁺ and 193 CD11c⁺ at T1 (left) or B1 (right). Associations for **b** are calculated using Pearson rank 194 correlation and are shown with Pearson trend lines for visualization. (c) Percentage RBD⁺ 195 memory B cells that are CXCR5⁺ in the healthy donor (left, white), COVID-19-naïve PAD 196 (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts. Aggregate of 197 mean percentage of CXCR5⁺ cells in all groups is shown on right. (d) Percentage of RBD⁺ 198 double negative B cells that are CD11c⁺ CXCR5⁻ in the healthy donor (left, white), COVID-19-199 naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right, green) cohorts. 200 Aggregate of mean percentage of are CD11c⁺ CXCR5⁻ cells in all groups is shown on right. (e) 201 Percentage of RBD⁺ double negative B cells that are CD11c⁻ CXCR5⁺ in the healthy donor (left, 202 white), COVID-19-naïve PAD (middle left, red), and COVID-19-experienced PAD (middle right, 203 green) cohorts. Aggregate of mean percentage of are CD11c⁻ CXCR5⁺ cells in all groups is 204 shown on right. Statistical analyses in a, c-e were performed using mixed effects model (for 205 trends found between time points) or a two-way ANOVA (for trends found between groups in the 206 aggregate graphs) with Fisher's least significant difference testing. Significance testing between 207 time points was limited to comparisons relative to T1. On the aggregate graphs, error bars were 208 calculated based on the standard error of the mean. Above the aggregate graphs, a green 209 asterisk indicates a comparison between the COVID-19-naïve and healthy donor groups, a 210 purple asterisk indicates a comparison between the COVID-19-experienced and healthy donor groups (*, *p* < 0.05; **, *p* < 0.01; ***, *p* < 0.001). 211

Patient Number	Age range	Sex	Vaccine Type	Booster Type	Diagnosis	COVID-19 infection to 1st vaccine (days)
101	56-60	F	Pfizer	Pfizer	CVID	
102	21-25	F	Pfizer	Pfizer	CVID	
103	56-60	F	Pfizer		CVID	
104	41-45	F	Pfizer	Pfizer	CVID	
105	26-30	М	Pfizer	Pfizer	CVID	
106	61-65	F	Pfizer		CVID	
107	71-75	F	Pfizer	Pfizer	SAB	96
108	61-65	F	Pfizer	Pfizer	CVID	
109	36-40	F	J&J	Pfizer	SAB	
110	46-50	F	Pfizer	Pfizer	CVID	
111	56-60	F	Pfizer	Pfizer	CVID	
112	41-45	М	Moderna	Moderna	CVID	
114	31-35	F	Pfizer		SAB	90
115	16-20	F	Moderna		CVID	181
116	26-30	F	J&J		SAB	
117	81-85	F	Moderna		CVID	
118	61-65	F	Moderna		CVID	
119	21-25	F	Pfizer	Pfizer	Hypogam	276
120	41-45	F	Moderna	Moderna	CVID	
121	66-70	F	Pfizer	Pfizer	SAB	
122	46-50	F	Pfizer		CVID	117
123	66-70	F	Pfizer	Pfizer	Hypogam	
124	51-55	F	Moderna		CVID	222
125	56-60	F	Moderna		Hypogam	106
126	56-60	М	J&J	Pfizer	CVID	
127	56-60	F	Pfizer	Pfizer	CVID	
128	61-65	F	Pfizer	Pfizer	Hypogam	
129	36-40	F	Pfizer	Pfizer	CVID	
130	46-50	F	Moderna	Moderna	SAB	144
131	26-30	F	Pfizer		CVID	36
368-05	36-40	М	Pfizer		Healthy donor	
368-17	36-40	М	Pfizer		Healthy donor	
368-24	51-55	F	Pfizer		Healthy donor	
368-25	41-45	F	Pfizer		Healthy donor	
368-27	46-50	М	Pfizer		Healthy donor	
368-29	26-30	F	Pfizer		Healthy donor	
368-34	26-30	М	Pfizer		Healthy donor	
368-36	46-50	F	Pfizer		Healthy donor	
368-37	41-45	М	Pfizer		Healthy donor	
368-38	41-45	F	Pfizer		Healthy donor	
368-40	31-35	F	Pfizer		Healthy donor	

Table S1. Characteristics of patient cohort

F, female; M, male; CVID, common variable immune defeiciency; hypogam, hypogammaglobulinemia; SAB, specific antibody deficiency disorder.

Patient Number	B cells (% of Live)	lgD ^₀ (% of CD19⁺)	lgD⁰ CD27⁺ (% of CD19⁺)	CD3⁺ T cells (% of Live)	CD4 ⁺ T cells (% of CD3 ⁺)	CD8 ⁺ T cells (% of CD3 ⁺)	CD4 ⁺ /CD8 ⁺ Ratio
101	4.07	34.3	18.8	34.6	57.6	10	5.76
102	5.21	12.5	5.16	28.3	47.4	28.2	1.68
103	4.74	11.7	4.61	50.2	51.4	24.5	2.10
104*	2.9	7.81	0.53	7.72	44.2	13.2	3.35
105	4.21	11.4	5.51	10.3	32.4	26.1	1.24
106*	6.13	5.63	1.68	12.7	52.9	8.48	6.24
107	3.02	27.1	15.1	17.1	42.9	18.9	2.27
108	4.42	30.6	17.1	11.8	45.7	15.1	3.03
109	9.89	12.8	8.27	16.5	48.6	16.9	2.88
110	3.61	32	18.1	18.1	49.3	18	2.74
111	4.01	44.5	34.5	15.2	47.8	16	2.99
112*	8.5	10.7	1.53	14.9	34.6	36.5	0.95
114	6.65	30.9	20.1	24.9	56.4	16.3	3.46
115	6.78	24.6	18.1	15	43.6	22.9	1.90
116	1.61	18.8	11.9	15.7	38.1	27.3	1.40
117	4.45	14.5	4.97	17.2	50.1	4.8	10.4
118	4.67	14.7	10.3	17.6	46.5	15.6	2.98
119	4.95	22.8	11.9	15.3	47.5	17.4	2.73
120	6.99	31.7	11.9	17.6	46.1	11.3	4.08
121	7.43	21.8	18.2	19.6	54.9	8.01	6.85
122	6.54	48.9	11	18.6	39.9	9.3	4.29
123	8.75	10.9	39.8	17.6	55	5.18	10.6
124	8.08	17.9	4.09	17.2	48.6	21.5	2.26
125	10.1	13.3	11.3	19.9	50.3	21.5	2.34
126*	5.89	11.4	6.62	17.7	48.5	14	3.46
127	4.92	17.1	4.82	19.6	56.7	16.4	3.46
128	2.77	29.5	3.09	16.3	44.9	19.9	2.26
129	8.45	8.89	20.8	17.5	44.1	26.6	1.66
130	6.74	33.9	3.54	18.4	46	27.2	1.69
131	4.43	8.39	25.3	12.7	39.1	31.2	1.25
368-05	10.7	12.3	8.52	30.8	47.3	32	1.48
368-17	8.85	25.1	15.1	19.9	57.5	8.68	6.62
368-24	7.82	16.3	11.8	28.7	60.8	12.1	5.02
368-25	13.1	22.9	17.3	21	48.9	10.4	4.70
368-27	3.12	24.8	22.4	44.5	33.3	22.3	1.49
368-29	8.19	21.3	14.1	26.6	48.3	19.2	2.52
368-34	15.7	8.93	6.25	33.6	43.7	11.3	3.87
368-36	6.64	20.8	16	24.2	54	16.3	3.31
368-37	6.88	23.9	18.5	22.6	48.4	6.98	6.93
368-38	7.05	7.13	4.5	11.7	44.7	10.1	4.43
368-40	9.09	27.1	17.6	24.3	48.2	16	3.01

Table S2. Cellular phenotype of patient cohort* Patients classified as non-responders (IgDlo Spike+ B cell response <0.02% of total B cells at day 7 to 28 post</td> vaccination).

Patient number	Most Recent CBC		Lymphocyte Subpopulation at the Time of Diagnosis					Immunoclobulin levels at the Time of Diagnosis		Most Recent	
	WBC	ALC	CD3	CD4	CD8	CD19	CD16/56	lgG	lgA	lgM	ige
Normal range	3.8 - 9.9 (1000s per mm ³)	1,000 - 3,300 (per mm ³)	661 - 1963 (per mm ³)	490 - 1294 (per mm ³)	187 - 781 (per mm ³)	110 - 488 (per mm ³)	76 - 467 (per mm³)	700 - 1600 mg/dL	75 - 400 mg/dL	40 - 230 mg/dL	mg/dL
101	5.8	2400	2118	1668	470	283	258	477	53	62	1065
102	4	1000	895	426	432	227	127	560	62	24	1134
103	4.5	1674	1450	934	456	187	180	566	140	106	828
104*	5.1	1000	818	601	193	251	18	<40	<4	<5	725
105	12	1500	974	384	487	280	221	<300	<10	<25	947
106*	7.2	1600						432	89	95	830
107	6.5	1900	1109	775	294	80	88	514	72	165	505
108	9.5	3500		Repo immur	orted no lology c	rmal in linic not	9	529	188	35	938
109	6.4	1100						895	142	105	1345
110	4.8	1700	1632	859	738	184	59	1304	82	37	1462
111	5.2	860						465			836
112*	4.3	1000	1162	375	663	134	151	1850	<25	<19	1303
114	8.3	1900	1702	1054	547	243	41	911	221	58	1291
115	15.6	2400						340	12	reported nl	1261
116	8	2400	1974	1167	690	262	71	983	162	52	983
117	5.4	1600	2194	1646	549	462	144	553	175	49	1143
118	7.3	1700		Reported normal in immunology clinic note			9	647	<4	<5	758
119	5	2200	2055	1396	790	211	79	473	120	167	877
120	8.3	2600	1848	1282	501	157	199	528	136	155	1164
121	6.2	2400	859	716	119	95	227	622	133	137	989
122	10.6	2720	3300	2274	1026	580	446	606	204	30	743
123	8	1500	1055	835	205	315	158	665	162	45	887
124	9.1	1190	Reported low NK cells only in immunology clinic note				502	42	95	547	
125	4.9	2000	1837	1086	725	475	308	656	270	10	657
126*	4.5	1600	Rep	Reported low CD19 at 39, all others normal in immunology note				<200	66	<25	860
127	3.8	1400	925	638	287	64	43	516	<25	521	781
128	7.2	800	655	389	236	209	78	629	196	80	990
129	5	1420						261	<10	<25	1240
130	6.27	1610						814	99	198	1145
131	10.79	1700						346	<10	<25	1036

Table S3. PAD patient laboratory values

CBC - complete blood count; WBC - white blood count, ALC - absolute lymphocyte count; Ig - immunoglobulin; dL - deciliter. Empty cells (dashed lines) indicate that the test was not performed.

* Patients classified as non-responders (IgDlo Spike+ B cell response <0.02% of total B cells at day 7 to 28 post vaccination).

Patient	S. pneumoniae Titer**	Tetanus Titer IU/ml****	Diphtheria Titer IU/ml****	
101	8/23	8/23 N/A		
102	7/23	0.51		
103	10/23	Positive	Positive	
104*	0/23	Positive		
105	0/23***	Negative		
106*	4/13	4.59		
107	14/23	0.97	0.09	
108	2/23	0.06	0.01	
109	6/23	>7	2.34	
110	5/23	N/A		
111	9/14	0.98		
112*		N/A		
114	12/23	1.56		
115	Unprotective			
116	14/23	0.36	Positive	
117	11/23	0.01		
118				
119	19/23	0.45		
120	14/23	>2.24		
121	8/23	0.46		
122	10/23	0.72		
123	20/23	>2.24		
124	2/24			
125	7/23	2.2		
126*	3/24***	0.24	Undetectable	
127	0/13			
128	14/23	0.87	0.07	
129	Unprotective			
130	0/23	2.75		
131		1.73	0.35	

Table S4. PAD patient responses to other vaccine antigens at the time of diagnosis

IU - international unit. N/A - data was obtained but not available in the medical record. Dashed lines indicate that the test was not performed.

* Patients classified as non-responders (IgDlo Spike+ B cell response <0.02% of total B cells at day 7 to 28 post vaccination).

** Indicates the number of tested anti-*Streptococcus pneumoniae* serotypes with a level above $1.3 \mu g/ml$ for ≥ 17 tested serotypes.

*** Pre-pneumovax booster values; patient started on immunoglobulin replacement prior to post-booster recheck.

**** A value of \geq 0.01 IU/ml is considered positive. In some records, a positive notation was indicated but no value was provided.